Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 22,996 shares of Biohaven Pharmaceutical stock in a transaction on Friday, January 5th. The shares were sold at an average price of $30.03, for a total value of $690,569.88. Following the completion of the transaction, the insider now owns 6,278,504 shares in the company, valued at approximately $188,543,475.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.06, for a total value of $2,551,522.86.
  • On Wednesday, January 3rd, Portage Biotech Inc. sold 35,650 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $28.61, for a total value of $1,019,946.50.

Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) opened at $27.09 on Thursday. The firm has a market capitalization of $975.72 and a price-to-earnings ratio of -5.19. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $17.00 and a 52-week high of $39.51.

A number of brokerages recently weighed in on BHVN. Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Canaccord Genuity began coverage on Biohaven Pharmaceutical in a research report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, December 11th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. Finally, BidaskClub lowered Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $36.14.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc bought a new stake in Biohaven Pharmaceutical during the 3rd quarter worth $119,000. Nationwide Fund Advisors acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth about $214,000. American International Group Inc. acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth about $251,000. State of Wisconsin Investment Board acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth about $262,000. Finally, Susquehanna International Group LLP acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth about $302,000. Institutional investors and hedge funds own 47.76% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Portage Biotech Inc. Sells 22,996 Shares” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/11/biohaven-pharmaceutical-holding-co-ltd-bhvn-major-shareholder-portage-biotech-inc-sells-22996-shares.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related stocks with our FREE daily email newsletter.